OncoMatch/Clinical Trials/NCT05125055
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Is NCT05125055 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for oral squamous cell carcinoma.
Treatment: Toripalimab (anti-programmed death-1 inhibitor) · Albumin paclitaxel · Cisplatin · Docetaxel · 5-Fluorouracil — To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the efficacy in patients with locally advanced OSCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anticancer treatments
Exception: unless grade 2 or higher toxic reactions have resolved
Unresolved grade 2 (CTCAE 5.0) or higher toxic reactions caused by previous anticancer treatments
Cannot have received: radiation therapy to head and neck
Known history of radiation to head and neck
Lab requirements
Blood counts
WBCs >3,000/mm3, hemoglobin >8 g/L, platelets >80,000/mm3
Kidney function
Serum creatinine <1.5 times the upper limit of normal
Liver function
ALAT/ASAT <2.5 times the upper limit of normal and bilirubin <1.5 times the upper limit of normal
Blood routine: white blood cells (WBCs) >3,000/mm3, hemoglobin >8 g/L, platelets >80,000/mm3; Liver function: ALAT/ASAT <2.5 times the upper limit of normal and bilirubin <1.5 times the upper limit of normal; Renal function: Serum creatinine <1.5 times the upper limit of normal; Coagulation function: INR, PT, APTT<1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify